COV2NOSE

Finland
|
2025-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination
  • Nasal vaccine

Grimberg

Israel
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Apo-Si-K170A-C76

Borys

Poland
|
2024-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Non pharmacological intervention
  • Rehabilitation
  • Education

Bonora

Italy
|
2014-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community

Cappelli

Italy
|
2021-2023
  • General population
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • Emergency department

CHARISMA

United Kingdom
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Influenza virus
  • Influenza
  • COVID-19
  • Blood sample
  • Nasopharyngeal swab

De la Matta Farrando

Spain
|
2022-2023
  • General population
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Diagnostics
  • Point of care tests

Diamantopoulou

Greece
|
2023-2024
  • General population
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Influenza virus
  • Adenovirus
  • Rhinovirus
  • Enterovirus
  • Human coronavirus NL63
  • Streptococcus pyogenes
  • Influenza
  • COVID-19
  • Adenovirus infection
  • Rhinovirus infection
  • Enterovirus infection
  • Streptococcus pyogenes infection
  • Diagnostics
  • Point of care tests

Dietz

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

FLUVAC EV-03

France
|
2016-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Influenza virus
  • Streptococcus pneumoniae
  • Influenza
  • Streptococcus pneumoniae infection
  • Pharmacological intervention
  • Vaccination

Hak

Italy The Netherlands
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza

Kodde

Germany Switzerland
|
2019-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • SARS-CoV-2
  • COVID-19